(2S,3R,4S,5R,6R)-2-[6-[[(3S,10R,13R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]hexylsulfanyl]-6-(hydroxymethyl)oxane-3,4,5-triol | 68354-92-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (2S,3R,4S,5R,6R)-2-[6-[[(3S,10R,13R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]hexylsulfanyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 68354-92-7
• 化学式: C₃₉H₆₈O₆S
• 分子量: 665.0
• InChiKey: CGPHGTBLEBJCCB-KXGIWWLXSA-N

物化性质

• 沸点：
  750.8±60.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  46
• 可旋转键数：
  15
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances, their use and method of preparing them
  申请人：Merck & Co., Inc.

  公开号：EP0028917A2

  公开（公告）日：1981-05-20

  Lipid vesicles comprise a lipid bilayer which includes an analog of a cell-surface receptor such as dicetyl phosphate, stearylamine, 6-(5-cholesten-3β-yloxy)hexyl 1-thio-β-L-fucopyranoside, 6-(5-cholesten-3β-yloxy)hexyl 1-thio-β-D-galactopyranoside, 6-(5-cholesten- 3β-yloxy)hexyl 1-thio-a- D-mannopyranoside, 6-(5-cholesten- 3-yloxy)hexyl 2-acetamido-3-deoxy- 1-thio-β-D-galactopyranoside, 6-(5-cholesten- 3β-yloxy)hexyl 6-amino-6-deoxy-1-thio- β-D-galactopyranoside or 6-(5-cholesten- 3p-yloxy)hexyl 6-amino-6-deoxy-1- thio-a-D-mannopyranoside, together with cholesterol, distearoyl phospatidylcholine and an effective amount of a physiologically compatible radioactive tracer or a cytotoxic or therapeutic agent as a part of the vesicles. The vesicles of this invention can be administered to mammalian, including human, hosts and have been found to release the contents of the vesicles in a predetermined manner, and in some cases to be rapidly concentrated in the lymphatic system and/or liver, lungs, or spleen of the host.

  脂质囊泡由脂质双分子层组成，其中包括细胞表面受体的类似物，如磷酸二十六烷基酯、硬脂胺、6-(5-胆甾烯-3β-氧基)己基 1-硫代-β-L-吡喃葡萄糖苷、6-(5-胆甾烯-3β-氧基)己基 1-硫代-β-D-吡喃半乳糖苷、6-(5-胆甾烯-3β-氧基)己基 1-硫代-β-D-吡喃半乳糖苷、6-(5-胆甾烯-3β-氧基)己基 1-硫代-a-D-吡喃甘露糖苷、6-(5-胆甾烯-3-氧基)己基 2-乙酰氨基-3-脱氧-1-硫代-β-D-吡喃半乳糖苷、6-(5-胆甾烯-3β-氧基)己基 6-氨基-6-脱氧-1-硫代-β-D-吡喃半乳糖苷或 6-(5-胆甾烯-3p-氧基)己基 6-氨基-6-脱氧-1-硫代-a-D-吡喃甘露糖苷，以及胆固醇、二硬脂酰磷脂酰胆碱和有效量的生理相容放射性示踪剂或细胞毒性或治疗剂，作为囊泡的一部分。本发明的囊泡可以给哺乳动物（包括人类）宿主服用，并且发现囊泡中的内容物会以预定的方式释放出来，在某些情况下会迅速集中在宿主的淋巴系统和/或肝、肺或脾中。
• New glycolipid compound useful as immunologic adjuvant and its preparation
  申请人：Merck & Co., Inc.

  公开号：EP0007277B1

  公开（公告）日：1983-02-09
• Cholesterol derivatives as intermediary products for the synthesis of immunologic adjuvants
  申请人：Merck & Co., Inc.

  公开号：EP0034835B1

  公开（公告）日：1984-12-12
• HIGH INTEGRITY LIPOSOMES AND METHOD OF PRERATION AND USE
  申请人：THE LIPOSOME COMPANY, INC.

  公开号：EP0389570B2

  公开（公告）日：2000-07-19
• ULTRASOUND CONTRAST AGENTS AND PROCESS FOR THE PREPARATION THEREOF
  申请人：Bracco Suisse SA

  公开号：EP1590006B1

  公开（公告）日：2010-09-08